Skip to main content

February 2013 Vol 6, No 1, Special Issue

Leukemia, Oncology
Ibrutinib: It’s Not Just for Leukemia
Audrey Andrews
Read More
Lymphoma
Ara-C Should Be Part of Conditioning Regimen in Young Patients with Mantle-Cell Lymphoma
Audrey Andrews
Read More
Can Prognostic Factors Guide the Treatment of DLBCL?
Mark Knight
Read More
Newly Discovered Genes in AML Can Identify Likely Response to Therapies
Mark Knight
Read More
Leukemia, Oncology
Molecular and Cytogenetic Assessments Infrequently Performed in Patients with CML Receiving First-Line Imatinib
Mark Knight
Read More
NIH Research Funding Cuts Would Have Devastating Impact on Hematology
Wayne Kuznar
Read More
Leukemia, Oncology
Alternatives to “7 + 3” Induction Therapy for AML Are Emerging
Wayne Kuznar
Read More
Leukemia, Oncology
Fast Response Identifies Patients with CML for Entry into Studies of Imatinib Discontinuation
Wayne Kuznar
Read More
Leukemia, Oncology
“Dramatic” Responses with Targeted Agent for Patients with CLL
Charles Bankhead
Read More
Leukemia, Oncology
New Oral TKI Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
Read More
Page 2 of 3
Results 11 - 20 of 30